Nasal neuroblastoma: review and case report
DOI:
https://doi.org/10.34287/MMT.3(46).2020.12Abstract
Sinonasal neuroblastoma is a rare malignant tumor with a wide variability of clinical manifestations, which may cause diagnostic difficulty and have hindered the progress in understanding the clinical course and improving outcomes of treatment. Patients often present with nasal obstruction, rhinorrhea, recurrent epistaxis, hyposmia, or anosmia. Treatment options consist of surgical resection and before or followed radiation and chemotherapy.
We present a case report and short literature review about diagnostic, clinical and histological classification and treatment of this tumor.
References
Gavrilyuk DV, Dykhno Yu.A., Khlebnikova FB Rare localization of melanoma. Sibirskoye meditsinskoye obozreniye. 2013; 5: 82–83.
Tabolinovskaya TD, Mudunov AM, Alieva SB, Orel NF et al. Esthesioneuroblastoma: clinical course, long-term results of treatment. Opukholi golovy i shei. 2016; 6 (1): 13–27. DOI: 10.17 650/2222-1468-2016-6-1-13-27.
Chadha S, Pannu KK. Esthesioneuroblastoma: A Case Report. Indian J Otolaryngol Head Neck Surg. 2011; 63 (1): 44–46. DOI: 10.1007/ s12070-011-0186-x.
Shah K, Perez-Ordóñez B. Neuroendocrine Neoplasms of the Sinonasal Tract: Neuroendocrine Carcinomas and Olfactory Neuroblastoma. Head Neck Pathol. 2016; 10 (1): 85–94. DOI: 10.1007/ s12105-016-0696-7.
Hwang S-K, Paek S-H, Kim DG et al. Olfactory Neuroblastomas: Survival Rate and Prognostic Factor. J Neuro-Oncology. 2002; 59 (3): 217–226. DOI: 10.1023/a:1019937503469.
Sampath P, Park MC, Huang D et al. Esthesioneuroblastoma (Olfactory Neuroblastoma) with Hemorrhage: An Unusual Presentation. Skull Base. 2006; 16 (3): 169–173. DOI: 10.1055/ s-2006-939677.
Suhodolo IV., Gereng EA. Structural and functional organization of cells of the diffuse endocrine system in the respiratory tract in normal and pathological conditions. Byulleten sibirskoy meditsiny. 2008; 1: 71–75.
Broich G, Pagliari A, Ottaviani F. Esthesioneuroblastoma: a general review of the cases published since the discovery of the tumour in 1924. Anticancer Res. 1997; 17 (4A): 2683–706.
Barnes L, Eveson JW, Reichart P, Sidransky D (Ed.) Pathology and Genetics of Head and Neck Tumours. WHO Classification of Tumours, 3rd Edition. Lyon: IARC Press; 2005.
Moran CA, Suster S. Neuroendocrine carcinomas (carcinoid, atypical carcinoid, small cell carcinoma, and large cell neuroendocrine carcinoma): current concepts. Hematol Oncol Clin North Am. 2007; 21 (3): 395-407. DOI:10.1016/j.hoc.2007.04.011.
Kusafuka K, Ferlito A, Lewis JS, Jr, et al. Large cell neuroendocrine carcinoma of the head and neck. Oral Oncol. 2012; 48: 211–215. DOI: 10.1016/j.oraloncology.2011.09.016.
Su SY, Bell D, Hanna EY. Esthesioneuroblastoma, neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma: differentiation in diagnosis and treatment. Int Arch Otorhinolaryngol. 2014; 18: S149–S156. DOI: 10.1055/s-0034-1390014.
Kayakabe M, Takahashi K, Okamiya T, et al. Combined small cell carcinoma of the sinonasal tract associated with syndrome of inappropriate secretion of antidiuretic hormone: a case report. Oncol Lett. 2014; 7: 1253–1256. DOI: 10.3892/ ol.2014.1882.
Bell D, Hanna EY, Weber RS et al. Neuroendocrine neoplasms of the sinonasal region. Head Neck. 2016; 38 (1): E2259–2266. DOI: 10.1002/hed.24152.
Kao HL, Chang WC, Li WY, et al. Head and neck large cell neuroendocrine carcinoma should be separated from atypical carcinoid on the basis of different clinical features, overall survival, and pathogenesis. Am J Surg Pathol. 2012; 36: 185–192. DOI: 10.1097/PAS.0b013e318236d822.
Xu B, Chetty R, Perez-Ordonez B. Neuroendocrine neoplasms of the head and neck: some suggestions for the new WHO classification of head and neck tumors. Head Neck Pathol. 2014; 8: 24–32. DOI: 10.1007/s12105-014-0531-y.
Likhacheva A, Rosenthal DI, Hanna E et al. Sinonasal neuroendocrine carcinoma: impact of differentiation status on response and outcome. Head Neck Oncol. 2011; 3: 32. DOI: 10.1186/1758-3284-3-32.
Basturk O, Tang L, Hruban RH. Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. Am J Surg Patol. 2014; 38 (4): 437–447. DOI: 10.1097/PAS.0000000000000169.
Klimstra DS, Beltran H, Lilenbaum R, Bergsland E. The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. Am Soc Clin Oncol Educ Book. 2015: 92–103. DOI: 10.14694/ EdBook_AM.2015.35.92.
Tang LN, Basturk O, Sue JJ, Klimstra DS. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas. Am J Surg Patol. 2016; 40 (9): 1192–1202. DOI: 10.1097/ PAS.0000000000000662.
Laster DR. Olfactory Neuroblastoma. Head Neck Pathol. 2009; 3 (3): 252–259. DOI: 10.1007/ s12105-009-0125-2.
Abdel-Rahman O, Kamal K. Sphenoidal esthesioneuroblastoma treated with sequential chemo radiotherapy: a case report and review of the literature. J Cancer Res Ther. 2014; 10 (4): 1101-1103. DOI: 10.4103/0973-1482.146110.
Peng X, Liu Y, Peng X, Wang Z et al. Clinical features and the molecular biomarkers of olfactory neuroblastoma. Pathol Res Pract. 2018; 214 (8): 1123–1129. DOI: 10.1016/j.prp.2018.06.002.
Manelfe C, Bonafé A, Fabre P, Pessey J J. Computed tomography in olfactory neuroblastoma: one case of esthesioneuroepithelioma and four cases of esthesioneuroblastoma. J Comput Assist Tomogr. 1978; 2 (4): 412–420.
Rosengren J E, Jing B S, Wallace S, Danziger J. Radiographic features of olfactory neuroblastoma. AJR Am J Roentgenol. 1979; 132 (6): 945–948.
Shanley D J, Buckner A B. Esthesioneuroblastoma demonstrated on bone scan. Correlation with CT and MRI. Clin Nucl Med. 1992; 17 (3): 231–232.
Bustillo A, Telischi F, Weed D et al. Octreotide scintigraphy in the head and neck. Laryngoscope. 2004; 114 (3): 434–440.
DublinAB.BobinskiM.ImagingCharacteristics of Olfactory Neuroblastoma (Esthesioneuroblastoma). J Neurol Surg B Skull Base. 2016; 77 (1): 1–5. DOI: 10.1055/s-0035-1564053.
Zozulya YA, Verkhoglyadova TP, Shamaiev MI, Malysheva TA. Histobiological principles of the classification of the nervous system tumors and its clinical significance. Ukraíinskiy neyrokhírurgíchniy zhurnal. 2001; 1: 32–41.
Minkin AU. Comprehensive diagnosis and treatment of precancerous diseases and malignant tumors of the upper jaw, nasal cavity and accessory (MD). 2005. Moscow. Russian Federation.
Squillaci S. Olfactory neuroblastoma with focal ganglioneuroblastic differentiation: a case report with literature review. Pathologica. 2014; 106 (2): 61–66.
Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer. 1976; 37 (3): 1571–1576.
Morita A, Ebersold MJ, Olsen KD et al. Esthesioneuroblastoma: prognosis and management . Neurosurgery. 1993; 32 (5): 706–715.
Tajudeen BA, Arshi A, Suh JD et al. Esthesioneuroblastoma: An Update on the UCLA Experience, 2002–2013. J Neurol Surg B Skull Base. 2015; 76 (1): 43–49. DOI: 10.1055/s-0034-1390011.
Palejwala SK, Sharma S, Le CH et al. Complications of Advanced Kadish Stage Esthesioneuroblastoma: Single Institution Experience and Literature Review. Cureus. 2017; 9 (5): e1245. DOI: 10.7759/cureus.1245.
Biller HF, Lawson W, Sachdev VP, Som P. Esthesioneuroblastoma: surgical treatment without radiation. Laryngoscope. 1990; 100 (11): 1199-1920. DOI:10.1288/00005537-199011000-00013
Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970-1990. Laryngoscope. 1992; 102 (8):843–849.
Konuthula N, Iloreta AM, Miles B et al. Prognostic significance of Kadish staging in esthesioneuroblastoma: An analysis of the National Cancer Database. Head Neck. 2017; 39 (10): 1962–1968. DOI: 10.1002/hed.24770.
Joshi RR, Husain Q, Roman BR et al. Comparing Kadish, TNM, and the modified Dulguerov staging systems for esthesioneuroblastoma. J Surg Oncol. 2019; 119 (1): 130–142. DOI: 10.1002/jso.25293.
Riazimand S H, Brieger J, Jacob R, Welkoborsky H J, Mann W J. Analysis of cytogenetic aberrations in esthesioneuroblastomas by comparative genomic hybridization. Cancer Genet Cytogenet. 2002; 136 (1):53–57. DOI: 10.18632/oncotarget.9683.
Holland H, Koschny R, Krupp W. et al.Comprehensive cytogenetic characterization of an esthesioneuroblastoma. Cancer Genet Cytogenet. 2007; 173 (2): 89–96. DOI: 10.1016/j. cancergencyto.2006.09.024.
Faragalla H, Weinreb I. Olfactory neuroblastoma: a review and update. Adv Anat Pathol. 2009; 16 (5): 322–331. DOI: 10.1097/ PAP.0b013e3181b544cf.
Cohen ZR, Marmor E, Fuller GN, DeMonte F. Misdiagnosis of olfactory neuroblastoma. Neurosurg Focus. 2002; 12 (5): e3. DOI:10.3171/ foc.2002.12.5.4.
Renner G. Small cell carcinoma of the head and neck: a review. Semin Oncol. 2007; 34 (3): 3–14. DOI: 10.1053/j.seminoncol.
Hyams VJ, Batsakis JG, Michaels L. Tumors of the upper respiratory tract and ear. Armed Forces Institute of Pathology Fascicles, 2nd series. Washington. American Registry of Pathology Press. 1988.
Andrew M. Bellizzi, MD, T. David Bourne et al. The Cytologic Features of Sinonasal Undifferentiated Carcinoma and Olfactory Neuroblastoma. Am J Clin Pathol 2008; 129 (3): 367–376. DOI: 10.1309/C00WN1HHJ9AMBJVT.
Olsen K D, DeSanto L W. Olfactory neuroblastoma. Biologic and clinical behavior. Arch Otolaryngol. 1983; 109 (12):797–802.
Jekunen A P, Kairemo K JA, Lehtonen H P, Kajanti M J. Treatment of olfactory neuroblastoma. A report of 11 cases. Am J Clin Oncol. 1996; 19 (4): 375–378.
Koch M, Constantinidis J, Dimmler A et al. Long-term experiences in the therapy of esthesioneuroblastoma. Laryngorhinootologie. 2006; 85 (10): 723–730. DOI: 10.1055/s-2006-925298.
NunleySR,KlassC,McLeanJNetal.Combined modality therapy of esthesioneuroblastoma. Otolaryngol Head Neck Surg. 2007; 136 (6): 998–1002. DOI: 10.1016/j.otohns.2006.11.051
Planek ME, Merzianu M, Mashtare TL et al. Improved survival following surgery and radiation therapy for olfactory neuroblastoma: analysis of the SEER database. Radiation Oncology. 2011; 6: 41.
Rastogi M, Bhatt M, Chufal K et al. Esthesioneuroblastoma treated with non-craniofacial resection surgery followed by combined chemotherapy and radiotherapy: An alternative approach in limited resources. Jpn J Clin Oncol. 2006; 36 (10): 613–619. DOI: 10.1093/jjco/hyl086
Kim HJ, Kim CH, Lee BJ et al. Surgical treatment versus concurrent chemoradiotherapy as an initial treatment modality in advanced olfactory neuroblastoma. Auris Nasus Larynx. 2007; 34 (4): 493–498. DOI: 10.1016/j.anl.2007.02.005
Planek ME, Merzianu M, Mashtare TL et al. Improved survival following surgery and radiation therapy for olfactory neuroblastoma: analysis of the SEER database. Radiation Oncology. 2011; 6: 41.
Patel SG, Singh B, Stambuk HE et al. Craniofacial surgery for esthesioneuroblastoma: report of an international collaborative study. J Neurol Surg B Skull Base. 2012; 73 (3): 208–220. DOI: 10.1055/s-0032-1311754
Polin RS, Sheehan JP, Chenelle AG, et al. The role of preoperative adjuvant treatment in the management of esthesioneuroblastoma: the University of Virginia experience. Neurosurgery. 1998; 42: 1029–1037.
Diaz EM, Johnigan RH, Pero C et al. Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center. Head Neck. 2005; 27 (2): 138–149. DOI: 10.1002/hed.20127.
Lapierre A, Selmaji I, Samlali H et al. Esthesioneuroblastoma: A single institution's experience and general literature review. Cancer Radiother. 2016; 20 (8): 783–789. DOI: 10.1016/j.canrad.2016.05.015.
Gruber G, Laedrach K, Baumert B et al. Esthesioneuroblastoma: irradiation alone and surgery alone are not enough. Int J Radiat Oncol Biol Phys. 2002; 54 (2): 486–491. DOI: org/10.1016/S0360-3016(02)02941-3.
McElroy EA, Buckner JC, Lewis JE. Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience. Neurosurgery. 1998; 42: 1023–1027; discussion 1027–1028.
Kim DW, Jo YH, Kim JH, et al. Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma. Cancer. 2004; 101 (10): 2257–2260. DOI:10.1002/ cncr.20648.
Porter AB, Bernold DM, Giannini C et al. Retrospective review of adjuvant chemotherapy for esthesioneuroblastoma. J Neurooncol. 2008; 90 (2): 201–204. DOI: 10.1007/s11060-008-9645-y.
Kiyota N, Tahara M, Fujii S, et al. Nonplatinum-based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma: A retrospective analysis of 12 cases. Cancer. 2008; 112 (4): 885–891. DOI: 10.1002/ cncr.23246.
Aljumaily RM, Nystrom JS, Wein RO. Neoadjuvant chemotherapy in the setting of locally advanced olfactory neuroblastoma with intracranial extension. Rare Tumors. 2011; 3 (1): е1. DOI: 10.4081/rt.2011.e1.
Kumar R, Ghoshal S, Bharti S, Das A, Khosla D, Kumar N, Kapoor R, Sharma SC. Survival and failure outcomes in locally advanced esthesioneuroblastoma: a single centre experience of 15 patients. Eur Arch Otorhinolaryngol. 2013; 270 (6): 1897–1901. DOI: 10.1007/s00405-012-2280-4.
Gandhoke CS, Dewan A, Gupta D et al. A rare case report of mixed olfactory neuroblastoma: Carcinoma with review of literature. Surg. Neurol. Int. 2017; 26 (8): 83. DOI: 10.4103/sni.sni_30_17.
Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970–1990. Laryngoscope. 1992; 102: 843–849.
Ow TJ, Hanna EY, Roberts OB et al. Optimization of long-term outcomes for patients with esthesioneuroblastoma. Head Neck. 2014; 36 (4): 524–530. DOI: 10.1002/hed.23327.
Konuthula N, Iloreta AM, Miles B et al. Prognostic significance of Kadish staging in esthesioneuroblastoma: An analysis of the National Cancer Database. Head Neck. 2017; 39 (10): 1962–1968. DOI: 10.1002/hed.24770.
Van Gompel J J, Giannini C, Olsen K D. et al. Long-term outcome of esthesioneuroblastoma: Hyams grade predicts patient survival. J Neurol Surg B Skull Base. 2012; 73 (5):331–336. DOI: 10.1055/s-0032-1321512.
Kaur G, Kane A J, Sughrue M E. et al. The prognostic implications of Hyam's subtype for patients with Kadish stage C esthesioneuroblastoma. J Clin Neurosci. 2013; 20 (2): 281–286. DOI: 10.1016/j.jocn.2012.05.029.
Joshi RR, Husain Q, Roman BR et al. Comparing Kadish, TNM, and the modified Dulguerov staging systems for esthesioneuroblastoma. J Surg Oncol. 2019; 119 (1): 130–142. DOI: 10.1002/jso.25293.
